Roche inks $36.5M deal with Dualitas to screen 300,000 bispecific antibody combos for inflammatory diseases
Roche has entered a collaboration with Dualitas to explore next-generation bispecific antibodies for inflammatory and immunology indications. The partnership involves screening 300,000 novel antibody combinations, with Roche providing an initial payment of $36.5 million. The deal aims to uncover new therapeutic approaches beyond current bispecific formats.
Roche’s new collaboration with Dualitas focuses on screening a vast library of 300,000 antibody combinations, a scale that suggests an effort to move beyond conventional bispecific designs. The initial $36.5 million payment signals Roche’s commitment to exploring this untapped space for inflammatory and immunology treatments.
This deal reflects a broader industry push toward more complex biologic formats, where pairing different antibody domains may yield greater selectivity or efficacy. By casting a wide net, the partners hope to identify candidates that current approaches have missed, though no specific targets or diseases have been disclosed.
If successful, this screening approach could accelerate discovery of new therapies for chronic inflammatory conditions, potentially offering patients more targeted options with fewer side effects. The scale of screening may also lower early-stage research costs across the field. However, outcomes remain uncertain, and any impact on patient care would likely take years to materialize, affecting researchers, investors, and eventually clinicians and those living with autoimmune diseases.